▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024Priorities
▪ First-Quarter 2024 Revenues of $14.9 Billion– Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decreasein Revenues of 19%– Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 11% Operationally
▪ First-Quarter 2024 Reported(2) Diluted EPS of $0.55 and Adjusted(3) Diluted EPS of $0.82– Both Include an $0.11 Favorable Impact from Final Revenue Adjustment Reflecting Actual EUA-labeledTreatment Courses of Paxlovid Returned by U.S. Government(4)
▪ On Track to Deliver at Least $4 Billion in Net Cost Savings by End of 2024 from Previously Announced CostRealignment Program(5)
▪ Reaffirms Full-Year 2024 Revenue Guidance(6) of $58.5 to $61.5 Billion and Raises Adjusted(3) Diluted EPSGuidance to $2.15 to $2.35
NEW YORK, Wednesday, May 1, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for the first quarterof 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024financial guidance(6).The first-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as thequarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.
点击阅读原文了解更多详情